Parenteral Administration of Capsule Depolymerase EnvD Prevents Lethal Inhalation Anthrax Infection

David Negus, a Julia Vipond, b Graham J. Hatch, b Emma L. Rayner, b Peter W. Taylor a

a School of Pharmacy, University College London, London WC1N 1AX, UK
b Public Health England, Porton Down, Salisbury SP4 0JG, UK

Running title: Prevention of lethal anthrax

#Address correspondence to Peter Taylor, peter.taylor@ucl.ac.uk
ABSTRACT Left untreated, inhalation anthrax is usually fatal. Vegetative forms of *Bacillus anthracis* survive in blood and tissues during infection due to elaboration of a protective poly-γ-D-glutamic acid (PDGA) capsule that permits uncontrolled bacterial growth *in vivo*, eventually leading to overwhelming bacillosis and death. As a measure to counter threats from multi-drug-resistant strains, we are evaluating the prophylactic and therapeutic potential of the PDGA depolymerase EnvD, a stable and potent enzyme which rapidly and selectively removes the capsule from the surface of vegetative cells. Repeated intravenous administration of 10 mg/kg recombinant EnvD to mice infected with lethal doses of *B. anthracis* Ames spores by inhalation prevented the emergence of symptoms of anthrax and death; all animals survived the five day treatment period and 70% survived to the end of the 14 day observation period. In contrast to sham-treated animals, the lungs and spleen of rEnvD-dosed animals were free of gross pathological changes. We conclude that rEnvD has potential as an agent to prevent the emergence of inhalation anthrax in infected animals and is likely to be effective against drug resistant forms of the pathogen.
INTRODUCTION

*Bacillus anthracis* featured in offensive weapons programs in the USA and former Soviet Union during the last century (1) and has been identified by the World Health Organization, the United Nations and the Working Group on Civilian Defense (WGCB) as a pathogen of great concern. The WGCB has highlighted a limited number of microorganisms that could cause infections in sufficient numbers to cripple a city or region and *B. anthracis* is one of the most serious of such threat agents (2). Their spores are able to survive in hostile environments for many decades and, in aerosolized form, can travel significant distances on prevailing winds, disseminating over a wide area. Accidental release of anthrax spores as an aerosol from a military facility in Sverdlovsk in 1979 resulted in at least 79 cases of anthrax and 68 deaths, demonstrating its lethal potential (3). These traits define *B. anthracis* as a potential threat agent, attractive to both rogue states and terrorist groups, and a cause of human and animal disease globally. The vegetative bacilli release toxin complexes that cause hemorrhage, edema and necrosis and are protected from host innate defenses by a capsule comprised of poly-γ-D-glutamic acid (PDGA) (4). In inhalation anthrax, endospores gain access to the alveolar spaces and are ingested by macrophages; they are then transported to regional lymph nodes where spore germination occurs after a variable period of dormancy (4, 5). Toxin-mediated clinical symptoms typically arise soon after the onset of rapid bacillary growth (2).

Effective treatment requires prompt and aggressive antibiotic therapy; a fluoroquinolone and an agent that inhibits protein synthesis such as linezolid are currently recommended by the Centers for Disease Control and Prevention (6). The consensus approach to prophylaxis and treatment of inhalation anthrax could be compromised by the release of *B. anthracis* carrying engineered antibiotic resistance genes and occasional reports have emerged of naturally occurring strains resistant to currently useful antibiotics (7, 8). Clearly, new agents or novel therapeutic and prophylactic modalities should be developed as a part of a comprehensive preparedness strategy. We previously demonstrated that parenteral administration of a capsule depolymerase with the capacity to rapidly and selectively remove the protective capsule from the bacterial surface can
resolve potentially lethal *Escherichia coli* infection in the neonatal rat (9, 10). Systemic anthrax is an attractive candidate for this approach as infections are attributable to a single, phylogenetically homogeneous bacterial species, all strains elaborate the unique PDGA capsule essential for pathogenesis (11) and hydrolysis of the outermost layer of the bacilli would confound attempts to circumvent antibiotic chemotherapy by the introduction of antibiotic resistance genes into *B. anthracis*. Here we report that early intravenous administration of rEnvD, a recombinant PDGA hydrolase elaborated by a consortium culture of soil bacteria, is able to prevent anthrax in mice infected by the inhalation route.

**MATERIALS AND METHODS**

Bacteria. *B. anthracis* Ames (NR-2324; pXO1+, pXO2+) was obtained from the Biodefense and Emerging Infections Research Resources Repository (Manassas, VA). Spores were prepared by fed batch culture in a 2 l bioreactor for 26 h at 37°C with stirring at 400 rpm, collected by centrifugation and washed in sterile distilled water. For spore challenge tests, suspensions (8 × 10⁹ CFU/ml) were prepared in sterile water. *Bacillus licheniformis* ATCC 9945a was purchased from the American Type Culture Collection and grown in Medium E containing 615 µM MnSO₄ in an orbital incubator (200 orbits/min) at 37°C (12).

Recombinant EnvD. The enzyme was expressed, refolded and purified as described previously (12).

Endotoxin was removed using Proteus Endotoxin Removal Columns (Abd Serotec, Oxford, UK) and removal confirmed with the Pierce LAL Chromogenic Endotoxin Quantitation Kit (Thermo Fisher, Rockford, USA). Purified rEnvD was stored in 20 mM Tris (pH 8.5) at -20°C until required.

**Impact of rEnvD on bacterial viability.** A culture (50 ml) from a single, heavily mucoid colony of *B. licheniformis* 9945a was grown to OD₆₀₀ 0.6 and examined by light microscopy to ensure only vegetative bacilli were present. Two aliquots of 1 ml were removed and rEnvD added to one aliquot to give a final protein concentration of 1µg/ml. An equal volume of phosphate buffered saline (PBS)
was added to the second. Both samples were incubated at 37°C for 15 min, serially diluted in PBS and plated onto Luria-Bertani agar. Plates were incubated at 37°C for 16 h and bacteria enumerated.

**Stability of rEnvD in serum.** Aliquots of rEnvD (final concentration 100 nM; in 1.6 ml Eppendorf tubes) were incubated at 37°C in serum from BALB/c mice (Sigma; total volume 200 μl) for up to 24 h and EnvD activity determined at regular intervals by Förster resonance energy transfer (FRET) utilizing the fluorescently labelled synthetic peptide substrate 5-FAM-(D-Glu-γ-γ-K(QXL™520)-NH₂ as previously described (12). Two tubes were used for each time point, to provide duplicate readings. In some experiments heat-inactivated (56°C, 30 min) serum was used and some assays were conducted in the presence of Roche complete protease inhibitor cocktail (Roche, Basel, Switzerland) at concentrations specified by manufacturer’s guidelines.

**Serum half-life.** Pairs of female adult BALB/c mice were dosed with 10 mg/kg rEnvD in 180 μl 20 mM Tris pH 8.5 by tail vein injection. Paired animals were sacrificed over a 24 h period, blood withdrawn by cardiac puncture and serum obtained. Serum was diluted twofold with 0.1 M Tricine, 0.1% CHAPS, pH 8.5 to a final volume of 200 μl and 100 μl transferred to each well of a black 96 well microtiter plate. All assays were run in duplicate. rEnvD activity was measured using the FRET assay described above with the exception that fluorescence was measured over a 4 min period. The concentration of enzyme in each sample was determined using a standard curve prepared in mouse serum. Area under the curve (AUC) was calculated by GraphPad Prism (GraphPad Software Inc., La Jolla, CA) using the trapezoid rule.

**Infection of mice with B. anthracis.** All animal studies were carried out in accordance with the UK Animals (Scientific Procedures) Act, 1986 and the Codes of Practice for the Housing and Care of Animals used in Scientific Procedures, 1989 following approval by the local ethical committee and the UK Home Office. Female BALB/c mice (minimum age 10 weeks; approximate body weight 20 g; food and water available ad libitum) were obtained from Charles River (Canterbury, UK) and infected by aerosol (13). Groups of ten mice were challenged with 10-50 minimum lethal doses (LD₅₀ 6 × 10⁴).
CFU; presented dose ~1.45 × 10^6 CFU) of *B. anthracis* spores with the AeroMP-Henderson apparatus. The challenge aerosol was generated using a six-jet Collison nebuliser (BGI Inc., Waltham, MA), the aerosol mixed with conditioned air in the spray tube and delivered to the nose of each animal through an exposure tube in which non-anesthetized mice were held in restraint tubes. Samples of the aerosol were obtained with an AGI30 glass impinger (Ace Glass Inc., Vineland, NJ) and the mean particle size determined with an aerodynamic particle sizer (TSI Instruments Ltd., High Wycombe, UK); these processes were controlled and monitored from an AeroMP management platform (Biaera Technologies, Hagerstown, MD). All-glass impinger samples were titrated by serial dilution and plated on trypticase soy agar prior to incubation at 37°C for 16-24 h.

Intravenous (i.v.) administration of rEnvD was initiated 12 h after spore challenge. The dosing regimen was guided by the stability of the enzyme in commercial mouse serum and by the rate of clearance of rEnvD from the circulation of adult female BALB/c mice. Each mouse received rEnvD (0.5-10 mg/kg) by injection at regular intervals up to 120 h after spore challenge; groups were comprised of ten individual animals. Control mice received i.v. injections of PBS (180 µl) at these time points. Additional groups of ten mice received oral doses of ciprofloxacin (118 mg/kg every 12 h for 14 days). Animals were monitored and assigned a clinical score at least twice daily up to 14 days after spore challenge and at least four times daily during critical periods (13). Clinical scores were based on severity of symptoms (ruffled fur, closed eyes, arched back, immobility, weight loss). Animals surpassing a threshold score were euthanized humanely by pentobarbital overdose. Surviving mice from each group were euthanized at day 14 after challenge. *Post mortem*, blood, lung and spleen samples were taken for enumeration of bacterial load: tissues were weighed and homogenized in sterile water using a Precellys24 tissue homogenizer (Bertin Technologies, Villeurbanne, France), the homogenates serially diluted in sterile water, plated onto trypticase soy agar and the plates incubated at 37°C for 16-24 h before enumeration. Further lung and spleen samples were placed in 10% neutral-buffered formalin for pathological evaluation. An additional group of ten mice was employed to evaluate pathological changes six days after spore challenge;
animals were culled 24 h after receiving their final dose of rEnvD on day five and blood and tissue samples removed. Kaplan-Meier log rank test was used to determine the significance of differences in survival between groups of animals and GraphPad Prism software (GraphPad, La Jolla, USA) was employed. For histological evaluation, formalin-fixed tissue samples were processed to paraffin wax and 3-5 µm sections cut and stained with hematoxylin and eosin. Sections were examined by light microscopy and evaluated subjectively. Slides were randomized by a third party before microscopic examination to avoid prior knowledge of group or treatment.

**RESULTS**

rEnvD is a promising candidate for *in vivo* attenuation of *B. anthracis* capsule expression.

Unusually, *envD* resides on the genome of a strain of *Pusillimonas nortemannii* but the enzyme is only produced when the bacteria are co-cultured with a strain of *Pseudomonas fluorescens* (12, 14). rEnvD showed strong sequence homology to bacterial dienelactone hydrolases and its enzymatic activity is restricted to the hydrolysis of γ-linkages in D- and L-glutamic acid-containing polymers ($k_{cat}$ $[h^{-1}]$ 72.6; $k_m$ [µM] 0.65; $k_{cat}/k_m$ [M⁻¹ s⁻¹ x 10⁴] 3.08 at 37°C). The enzyme retained enzymatic activity after accelerated storage at 37°C for 30 days and completely removed the capsule from *B. anthracis* Pasteur strain within 5 min at 37°C (12). Exposure of *Bacillus licheniformis* ATCC 9945a (induced to elaborate a PDGA polymer) to rEnvD resulted in rapid stripping of the capsule (12) but the viability of this surrogate strain was not significantly altered (2.5 × 10⁸ to 2.9 × 10⁸ CFU/ml over 15 min; $n$=6, Student’s $t >0.05$).

There is limited capacity for repeated parenteral injections in small animals. To guide the design of dosing regimens for the administration of rEnvD to infected BALB/c mice, we determined the retention of depolymerase activity in mouse serum and the serum half-life ($t_{1/2}$) following intravenous (i.v.) administration. The reduction in rEnvD activity following incubation at 37°C in murine serum as determined by FRET assay (12) followed first-order kinetics with $t_{1/2}$ of 177 min (Fig. 1A); approximately 20% of activity remained after 8 h incubation. Neither heat inactivation of serum
nor the presence of protease inhibitors had any impact on the rate of reduction of activity.

Elimination of rEnvD from the blood circulation of BALB/c mice was biphasic, with an initial rapid decrease in serum concentration (0.5 h to 1 h) followed by a slower elimination phase (2 h to 24 h) characteristic of first order kinetics (Fig. 1B). This elimination profile is typical of agents administered by the intravenous route (15); a rapid decrease in serum concentration due to distribution from the central circulation into the peripheral body tissues (alpha phase) followed by a gradual decrease in plasma concentration attributable to metabolism and excretion of the drug (beta phase). AUC was determined as 118 nM.h/l. Based on this data, we established a dosing regimen in which mice received rEnvD (0.5-10 mg/kg body weight) by i.v. injection 12 h, 24 h, 48 h, 72 h, 96 h and 120 h after spore challenge.

**rEnvD administration prevents inhalation anthrax in aerosol-challenged mice.** Typically, all animals in sham-treated (PBS) control groups met humane endpoints within 72 h (median time to death 48 h) whereas all mice treated with 10 mg/kg of rEnvD survived the treatment period (P<0.0001; log rank) (Fig. 2A). Nine days after termination of treatment, 70% of rEnvD-treated mice had survived (P<0.0001, compared to control animals). The protective effect of rEnvD was reflected in the comparative health status of the mice: abnormal clinical signs were absent from rEnvD-treated animals during the five-day period of enzyme administration (Fig. 2B). At six and fourteen days post-challenge and in contrast to controls, bacteria were not cultured from the blood or spleen of surviving rEnvD-treated mice from the tissue group; sham-treated mice were found to carry a high *B. anthracis* bioburden in the blood (mean $2.4 \times 10^4$ CFU/ml) and spleen (mean $5.84 \times 10^4$ CFU/mg) at time of post mortem examination (based on severity threshold score). High numbers of viable bacteria were also present in the lung of sham-treated animals at the same time point (mean $1.37 \times 10^5$ CFU/mg). In comparison to controls, a significant ($P=0.006311$) reduction in the lung bioburden was noted in EnvD-treated animals six days after spore challenge (mean $1.55 \times 10^2$ CFU/mg) compared to controls and a lower number (mean $2.07 \times 10^1$ CFU/mg) were present in the lung of surviving animals 14 days after challenge (Fig. 3).
Microscopic changes referable to infection with *B. anthracis* were observed in the lung and spleen of all control animals. In the lung, there was prominent pulmonary congestion and patchy haemorrhage, expanding septal cavities and numerous bacilli located in alveolar spaces, walls and within vessel lumena (bacteremia) (Fig. 4A). In the spleen, numerous bacilli within the red pulp sinusoids and vascular lumena were present in these control animals (data not shown). Further, splenic white pulp contained prominent degeneration and loss of lymphocytes, characterized by nuclear fragmentation and cellular paucity. In contrast, animals receiving rEnvD and surviving until study endpoints were found to be clear of gross pathological changes and bacilli were not visible within lung (Fig. 4B) or spleen tissue.

Experiments with 5 mg/kg rEnvD dosed over three days also demonstrated a high degree of protection from anthrax infection (100% survival at 3 days; 60% survival at 14 days) but 0.5 mg/kg rEnvD did not prevent the emergence of clinical symptoms and death; rEnvD administered for five days provided better protection than orally dosed ciprofloxacin administered by the oral route throughout the fourteen day period (Fig. 2C & D).

**DISCUSSION**

This study provides clear evidence that prompt serial i.v. administration of small quantities of EnvD prevents the onset and progression of inhalation anthrax in a robust murine model of invasive disease. Even though the strain employed in this study is highly toxigenic, removal of the capsule during the early stages of infection appears sufficient to confound the pathogenic potential of the invading bacteria and further supports the key role of the protective PDGA capsule in anthrax pathogenesis (4, 11), highlighting the requisite nature of the capsule for *in vivo* dissemination of vegetative bacilli. The study also adds to growing evidence that prophylaxis and treatment of severe systemic infections can be realised by agents that do not kill the target bacterial population *per se* but modify the phenotype of the pathogen in a way that is beneficial to the host (16). Further, this
approach has the potential to deliver exquisitely selective therapeutics that are unaffected by the presence of antibiotic resistance mechanisms.

Treatment of bacterial infections with capsule depolymerases was first explored over 80 years ago by Dubos, Avery and colleagues at the Rockefeller Institute for Medical Research. They used an enzyme preparation from cultures of a peat soil bacterium to selectively remove the polysaccharide capsule from the surface of type III pneumococci (17), the pathogen’s principle means of defense against immune attack. Intraperitoneal administration of enzyme extracts to mice prior to challenge with type III pneumococci gave rise to type III-specific protection (18), i.v. administration to rabbits with type III dermal infections resulted in early termination of the normally fatal infection (19) and the enzyme prevented dissemination, sterilized the blood and promoted early recovery in non-human primates infected by the intratracheal and intrabronchial routes (20).

In addition to our previous work on systemic neonatal E. coli infections (9, 10), capsule depolymerases have been shown to resolve potentially lethal experimental Klebsiella pneumoniae K1 infections in mice (21).

Recently, other attempts have been made to exploit PDGA depolymerases as anti-anthrax therapeutics. CapD is a γ-glutamyltranspeptidase elaborated by B. anthracis and catalyzes the attachment of PDGA to peptidoglycan, but also functions as a depolymerase, effecting the release of fusible PDGA fragments from the surface of producer strains (22). CapD mediates removal of the capsule and induces macrophage uptake and neutrophil killing in vitro (23). Intraperitoneal co-injection of CapD and vegetative B. anthracis Ames bacteria afforded some protection against infection in mice but no significant protection could be demonstrated when the enzyme was administered after challenge with Ames spores (24), almost certainly due to the labile nature of CapD (12, 20). rEnvD is a far more robust enzyme (12) and a better candidate for therapeutic development.

Current evidence suggests that although the toxin complex undoubtedly plays a vital role in anthrax pathogenesis, probably by suppression of the immune response in early stages of the
disease, death occurs from overwhelming bacteremia and sepsis due to uncontrolled bacterial proliferation and release of pro-inflammatory mediators (25). Thus, a therapeutic window may be available if treatment is initiated before extensive bacterial division occurs in the blood. Our results support this hypothesis: depolymerase administration initiated 12 h after aerosol challenge provided significant protection against systemic anthrax and prevented bacteremia and dissemination of bacilli to the spleen. This concurs with a previous report that the capsule is essential for hematogenous bacillary spread, as capsule negative mutants did not migrate to the spleen in experimental infections (11). In the current study, deaths generally occurred following cessation of treatment. Viable bacteria were present in the lung of rEnvD-treated mice after the treatment period and animals that subsequently succumbed to infection almost certainly died due to delayed germination of latent spores and after enzyme had been cleared from the blood circulation. B. anthracis spores are known to persist in the lung for extended periods: for example, latent spores have been isolated from the lung tissue of non-human primates months after initial exposure (26). The size of the mouse restricts the number of i.v. injections that can be given over a relatively short period of time and this issue will be addressed using larger species such as the rabbit. In addition, the mouse is particularly susceptible to death from systemic anthrax due to uncontrolled in vivo bacterial growth and a high quantitative level of bacteremia (27), factors which do not favour an anti-capsule therapeutic strategy. The relative susceptibility of humans to toxemia and infection in anthrax is poorly documented but the rabbit is used as an equivalent to human infection (27) and examination of rEnvD in this species will be an important next step.

**FUNDING INFORMATION**

This study was funded by project grant GA2014-001R from the British Society for Antimicrobial Chemotherapy, Centre for Defence Enterprise contract DSTLX1000088481 from the Defence Science and Technology Laboratory (Dstl) and project grant HF5E PoC-13-020 from UCL Business.
ACKNOWLEDGMENTS

This work was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.


7. Turnbull PCB, Sirianni NM, LeBron CI, Samaan MN, Sutton FN, Reyes AE, Peruski LF. 2004. MICs of selected antibiotics for *Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis,* and *Bacillus mycoides* from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol **42:**3626-3634.


12. **Negus D, Taylor PW.** 2014. A poly-γ-D-glutamic acid depolymerase that degrades the protective capsule of *Bacillus anthracis*. Molec Microbiol 91:1136-1147.


14. **Stabler RA, Negus D, Pain A, Taylor PW.** 2013. Draft genome sequences of *Pseudomonas fluorescens* BS2 and *Pusillimonas noertimanii* BS8, soil bacteria that cooperate to degrade the poly-γ-D-glutamic acid anthrax capsule. Genome Announc 1:e00057-12.


**FIG. 1** In vitro stability in serum and elimination of rEnvD from the circulation of BALB/c mice. A: Stability of rEnvD in BALB/c mouse serum; 100 nM of enzyme was incubated at 37°C in serum and activity determined by FRET assay (12). Enzyme activity in relative fluorescent units was converted to concentration of active enzyme by comparison to a standard curve. Error bars represent the range of three separate determinations; t\(_{1/2}\) in serum of rEnvD was 2.95 h (177 min). B: rEnvD in serum obtained from mice intravenously dosed with 10 mg/kg rEnvD. Serum was obtained by terminal bleed and enzyme activity determined by FRET assay; Serum concentration (Cp) of rEnvD was obtained by comparison to a standard curve. Error bars represent the range of three separate determinations performed in duplicate; t\(_{1/2}\) was calculated by determination of the elimination rate constant (K\(_e\)) and transformation of data to the natural log (ln) to produce a line of best fit for each phase with the slope equal to K\(_e\): t \(_{1/2} = \ln(2)/K_e\). The t\(_{1/2}\) for the initial alpha phase between 0.5 h and 1 h was 0.22 h (13 min) and for the beta phase between 2 h and 24 h was 2.71 h (163 min).

**FIG. 2** Impact of intravenous administration of rEnvD on inhalation anthrax in mice. Combined Kaplan-Meier survival plots (A, C) and cumulative mean clinical observation scores (B, D) for rEnvD-dosed, infected BALB/c mice. Mice were infected with *B. anthracis* Ames on day 0 by aerosol followed by tail vein administration of either 10 mg/kg rEnvD or PBS vehicle (A, B) or 0.5 mg/kg rEnvD (C, D) at the times indicated by arrows. Ciprofloxacin (118 mg/kg) was also administered orally for 14 days (C, D). Clinical observations were scored as described (13) and were based on severity of symptoms (ruffled fur, closed eyes, arched back, immobility, weight loss).

**FIG. 3** *B. anthracis* (CFU/mg tissue) in the spleen and lung of mice following rEnvD or PBS administration by the intravenous route; n=7-10, mean ±1 SD. PBS controls were culled when the clinical score reached threshold levels, as the animals were then close to death (13). Tissues were weighed and homogenized in sterile water, the homogenates serially diluted in sterile water, plated onto trypticase soy agar and the plates incubated at 37°C for 16-24 h.
FIG. 4 Pathology of lung tissue six days after inhalation of spores. Samples were fixed in 10% neutral-buffered formalin, processed to paraffin wax, sectioned to 3-5 µm, stained with HE and examined by light microscopy. Slides were randomized by a third party before microscopic examination to avoid prior knowledge of group or treatment. A: From animals receiving only PBS vehicle; region shows iatrogenic thickening of the alveolar walls due to the collapsed nature of the tissue. Arrows indicate bacilli located in alveolar spaces; Ve, vessel lumena. B: From animals receiving 10 mg/kg rEnvD over 5 days; image from region of inflated lung.